This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-15. Anything still debated is marked as such rather than presented as settled.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
== See also == S&P 1500 – US broad stock market index from S&P Dow Jones Indices Russell 2500 Index Russell 2000 Index – U.S. small-cap stock market index Russell 1000 Index – U.S. large-cap stock market index Wilshire 5000 – US total stock market index
== Evolution == GPxs are a key part of animal (including human) antioxidant defenses. They are also find in bacteria, plants, and fungi. GPx was the first selenoprotein discovered, with a highly reactive Sec residue at the active site. Comparison of GPx sequences from all these types of life suggest that the ancestral GPx did not contain selenium; instead, acquision of Sec happened early in animal evolution, before the sponges diverged from other animals. Humans have eight Gpx genes, but only five of them contain Sec (GPX1, GPX2, GPX3, GPX4, GPX6). The non-existence of Sec in GPX7 and GPX8 appears to be universal among animals. The loss of Sec (by replacement with Cys) in GPX5 was, however, a relatively recent event that happened after the divergence of humans from rodents. Rodents have independently lost the Sec in Gpx6, but kept it in their version of Gpx5. Human GPX5 and rodent Gpx6 retain vestigial SECIS elements indicative of their past.
=== NICE === The UK's National Institute for Health and Care Excellence (NICE) can pay from £100,000 to £300,000 per QALY (Quality Adjusted Life Year) for treatments of "very rare conditions". This is compared to under £20,000 for non-orphan drugs. In 2015, NICE held consultations with "patient groups, the Department of Health, companies, learned societies, charities and researchers" regarding the appraisal of medicines and other technologies. There was a call for more research into new processes, including:
In contrast with the previous study on PFK1, this study found that elevating OGT or O-GlcNAc upregulated PFK1, though the two studies are consistent in finding that O-GlcNAc levels are positively associated with flux through the pentose phosphate pathway. This study also found that decreasing O-GlcNAc selectively killed cancer cells via ER stress-induced apoptosis. Human pancreatic ductal adenocarcinoma (PDAC) cell lines have higher O-GlcNAc levels than human pancreatic duct epithelial (HPDE) cells. PDAC cells have some dependency upon O-GlcNAc for survival as OGT knockdown selectively inhibited PDAC cell proliferation (OGT knockdown did not significantly affect HPDE cell proliferation), and inhibition of OGT with 5S-GlcNAc showed the same result. Hyper-O-GlcNAcylation in PDAC cells appeared to be anti-apoptotic, inhibiting cleavage and activation of caspase-3 and caspase-9. Numerous sites on the p65 subunit of NF-κB were found to be modified by O-GlcNAc in a dynamic manner; O-GlcNAc at p65 T305 and S319 in turn positively regulate other modifications associated with NF-κB activation such as p300-mediated K310 acetylation and IKK-mediated S536 phosphorylation. These results suggested that NF-κB is constitutively activated by O-GlcNAc in pancreatic cancer. OGT stabilization of EZH2 in various breast cancer cell lines has been found to inhibit expression of tumor suppressor genes.
=== Geriatrics === Most antidepressants, including SNRIs, are safe and effective in the geriatric population. The geriatric population is at greater risk for adverse effects relating to drug interaction as they are more likely to experience polypharmacy. Decisions are often based on co-morbid conditions, drug interactions, and patient tolerance. Due to differences in body composition and metabolism, starting doses are often half that of the recommended dose for younger adults. Studies show that these factors also put the geriatric population at increased risk of adverse effects when treated with SNRIs but not with SSRIs.
Sources: en.wikipedia.org
By measuring the amount of radioactive decay of a radioactive isotope with a known half-life, geologists can establish the absolute age of the parent material. A number of radioactive isotopes are used for this purpose, and depending on the rate of decay, are used for dating different geological periods. More slowly decaying isotopes are useful for longer periods of time, but less accurate in absolute years. With the exception of the radiocarbon method, most of these techniques are actually based on measuring an increase in the abundance of a radiogenic isotope, which is the decay-product of the radioactive parent isotope. Two or more radiometric methods can be used in concert to achieve more robust results. Most radiometric methods are suitable for geological time only, but some such as the radiocarbon method and the 40Ar/39Ar dating method can be extended into the time of early human life and into recorded history. Some of the commonly used techniques are:
=== Axon terminal === Each corpuscle is associated with a myelinated axon; these are some of the largest and fastest-conducting sensory axons arising from the skin. Towards the center of the corpuscle, the axon loses its sheaths, ending as with a slight bulge at the center of the corpuscle. This axon terminal issues brief projections of unknown functional significance into gaps between the surrounding innermost lamellae; large mitochondria and small vessels aggregate near these projections.
A 2017 film adaptation of Wonder, starring Julia Roberts, Owen Wilson and Jacob Tremblay, was released in November 2017. A stage adaption premiered in 2025, with actor Garrett McNally, who has Treacher Collins syndrome himself, portraying the character in certain shows. Alison Midstokke, who appears in the drama film Happy Face (2018), is an actress and activist who has the condition.
=== Ferroelectrics and multiferroics === Some MOFs also exhibit spontaneous electric polarization, which occurs due to the ordering of electric dipoles (polar linkers or guest molecules) below a certain phase transition temperature. If this long-range dipolar order can be controlled by the external electric field, a MOF is called ferroelectric. Some ferroelectric MOFs also exhibit magnetic ordering making them single structural phase multiferroics. This material property is interesting for construction of memory devices with high information density. The coupling mechanism of type-I [(CH3)2NH2][Ni(HCOO)3] molecular multiferroic is spontaneous elastic strain mediated indirect coupling.
Sources: en.wikipedia.org
=== Location === The vocal folds are located within the larynx at the top of the trachea. They are attached at the back to the arytenoid cartilages, and at the front to the thyroid cartilage via Broyles ligament. They are part of the glottis. Their outer edges are attached to muscle in the larynx while their inner edges form an opening called the rima glottidis. They are constructed from epithelium, but they have a few muscle-fibres in them, namely the vocalis muscle which tightens the front part of the ligament near to the thyroid cartilage. They are flat triangular bands and are pearly white in color. Above both sides of the glottis are the two vestibular folds or false vocal folds which have a small sac between them.
== Pultronics today == Today (>1998), Pultronics is involved in the RFID industry with its active RFID systems for long-range wireless data communications. Tracking of goods/assets through a cold chain is a typical usage of such systems. Pultronics is also active in the micro-transmitter system design including design of ASICs resulting in miniature sized active tags.
Border tensions continued into the early 2000s, although the two countries cooperated in other areas. The PUP won a landslide victory in the 1998 national elections, and PUP leader Said Musa was sworn in as prime minister. In the 2003 elections the PUP maintained its majority, and Musa continued as prime minister. He pledged to improve conditions in the underdeveloped and largely inaccessible southern part of Belize. In 2005, Belize was the site of unrest caused by discontent with the PUP government, including tax increases in the national budget. On 8 February 2008, Dean Barrow was sworn in as prime minister after his UDP won a landslide victory in general elections. Barrow and the UDP were re-elected in 2012 with a considerably smaller majority. Barrow led the UDP to a third consecutive general election victory in November 2015, increasing the party's number of seats from 17 to 19. He said the election would be his last as party leader and preparations are under way for the party to elect his successor. On 11 November 2020, the People's United Party (PUP), led by Johnny Briceño, defeated the United Democratic Party (UDP) for the first time since 2003, having won 26 seats out of 31 to form the new government of Belize. Briceño took office as prime minister on 12 November. In 2023, Belize became the second Central American country to be awarded certification for the elimination of malaria by the WHO.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.